BioWorld

May 30, 2008

Kosan's Cancer Pipeline Attracts $5.50 Per Share BMS Buyout Bid

Kosan Biosciences Inc. is being snatched up by Bristol-Myers Squibb Co. for $5.50 per share, becoming the latest acquisition as big pharma struggles to fill dwindling pipelines. (BioWorld Today) Read More

FDA Documents Critical of Ligand's Promacta

Onconase Misses Endpoint, Rolling NDA to Proceed

NewCo News: EnzymeRx Makes a $14 Million Start with Uricase Acquisition

Drug Labeling Rule Proposed for Those Pregnant, Breastfeeding

Favrille Laying Off 132 After Specifid Fails Pivotal Trial

Other News To Note

Clinic Roundup

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...